Comparative Pharmacology
Head-to-head clinical analysis: DOLENE versus NUBAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLENE versus NUBAIN.
DOLENE vs NUBAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
Nalbuphine is a mixed opioid agonist-antagonist. It acts as an agonist at kappa opioid receptors and as an antagonist at mu opioid receptors, providing analgesia with a ceiling effect for respiratory depression.
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
10-20 mg IV, IM, or SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum daily dose 160 mg.
None Documented
None Documented
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
3.5–5 hours (terminal elimination half-life); clinically, in hepatic or renal impairment, half-life may be prolonged, requiring dose adjustment.
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Primarily renal (83% as unchanged drug and glucuronide conjugate); fecal excretion accounts for <5%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic